Molecular Partners Announces Participation in March Investor Conferences and Upcoming 2025 Financial Results
MWN-AI** Summary
Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech innovator focused on DARPin therapeutics, has announced its participation in several upcoming investor conferences. The company's CEO, Patrick Amstutz, will present at two notable events in March 2026. The first is the TD Cowen 46th Annual Health Care Conference in Boston, scheduled for March 2-4, where Amstutz will participate in a fireside chat on March 2 from 2:30 to 3:00 PM ET. This will be followed by the Leerink Partners Global Healthcare Conference in Miami, taking place from March 9-11, where he will engage in another fireside chat on March 9 from 4:20 to 4:50 PM EDT.
In addition to its conference participation, Molecular Partners will release its full-year 2025 financial report, along with its Annual Report, on March 12, 2026, at 4:00 PM EDT. Both chats will be accessible on the company's website under the investor section, providing an opportunity for stakeholders to gain insights into the company's ongoing projects and financial health.
Founded in 2004, Molecular Partners specializes in developing DARPins, a new class of protein therapeutics aimed at addressing unmet medical needs, particularly in oncology. The company is advancing multiple proprietary programs and collaborations with leading pharmaceutical entities. As Molecular Partners prepares for these events, it aims to share its vision and developments in delivering innovative cancer treatments.
Investors and stakeholders are encouraged to follow the upcoming announcements and discussions as the company continues to progress in its mission to provide effective therapeutic solutions in challenging medical landscapes.
MWN-AI** Analysis
Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a pioneer in DARPin therapeutics, has garnered attention with its upcoming participation in key investor conferences and the anticipated release of its full-year 2025 financial results on March 12, 2026. The company's strategic presence at prominent events, such as the TD Cowen and Leerink Partners conferences, underscores its commitment to maintaining investor engagement and enhancing market visibility.
Investors should prepare for key insights during CEO Patrick Amstutz's fireside chats, slated for March 2 and March 9, which may provide critical updates on the company's development pipeline and projected financial outlook. Given that Molecular Partners operates in a high-stakes biotech environment focused on innovative cancer therapies, any commentary related to clinical advancements or strategic partnerships during these events may serve as a bellwether for the company's future trajectory.
As the market awaits the financial results, the company’s performance metrics will be pivotal. A strong financial report could validate the strategic direction and investments made over the past year. Conversely, disappointing results may raise concerns about the viability of its clinical programs and cash runway. The mention of DARPins positions Molecular Partners in a niche area with potential for high reward, but it comes with inherent risks typical of clinical-stage biotech firms, underscored by the cautionary note regarding forward-looking statements.
For investors, monitoring stock movements around these key dates will be crucial. Any volatility in share prices post-announcement could present buying opportunities for those looking to capitalize on the long-term potential of DARPin therapeutics. As always, conducting thorough due diligence and considering the inherent risks associated with biotech stocks is advisable before making investment decisions.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics (“Molecular Partners” or the “Company”), today announced its attendance and presentations at upcoming investor conferences.
Molecular Partners will also issue its full-year 2025 financial report, along with its Annual Report, on March 12, 2026.
Details of the events:
TD Cowen 46th Annual Health Care Conference
Boston, MA, March 2-4, 2026
Molecular Partners CEO Patrick Amstutz will take part in a fireside chat on Monday, March 2 at 2.30-3.00 pm ET (8.30-9.00 pm CET).
Leerink Partners Global Healthcare Conference 2026
Miami, FL, March 9-11 March, 2026
Molecular Partners CEO Patrick Amstutz will take part in a fireside chat on Monday, March 9 at 4.20-4.50 pm EDT (9.20-9.50 pm CET).
Full Year 2025 Financial Results Announcement
Thursday, March 12, 2026 at 4.00 pm EDT (9.00 pm CET).
Both fireside chats will be made available on the Company’s website under the investor section.
About Molecular Partners AG
Molecular Partners AG (SIX: MOLN, NASDAQ: MOLN) is a clinical-stage biotech company pioneering a novel class of protein drugs known as DARPin therapeutics, for medical challenges other treatment modalities cannot readily address. Molecular Partners leverages the key properties of DARPins to design and develop differentiated therapeutics for cancer patients, including targeted radiopharmaceuticals and next-generation immune cell engagers. The Company has proprietary programs in various stages of pre-clinical and clinical development, as well as programs developed through partnerships with leading pharmaceutical companies and academic centers. Molecular Partners, founded in 2004, has offices in both Zurich, Switzerland and Concord, MA, USA. For more information, visit www.molecularpartners.com and find us on LinkedIn and Twitter / X @MolecularPrtnrs
For further details, please contact:
Seth Lewis, SVP Investor Relations & Strategy
Concord, Massachusetts, U.S.
seth.lewis@molecularpartners.com
Tel: +1 781 420 2361
Laura Jeanbart, PhD, Head of Portfolio Management & Communications
Zurich-Schlieren, Switzerland
laura.jeanbart@molecularpartners.com
Tel: +41 44 575 19 35
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements. Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995, as amended, including without limitation: implied and express statements regarding the clinical development of Molecular Partners’ current or future product candidates; expectations regarding timing for reporting data from ongoing clinical trials or the initiation of future clinical trials; the potential therapeutic and clinical benefits of Molecular Partners’ product candidates and its RDT and Switch-DARPin platforms; the selection and development of future programs; Molecular Partners’ collaboration with Orano Med including the benefits and results that may be achieved through the collaboration; and Molecular Partners’ expected business and financial outlook, including anticipated expenses and cash utilization for 2026 and its expectation of its current cash runway. These statements may be identified by words such as “aim”, "anticipate", “expect”, “guidance”, “intend”, “outlook”, “plan”, “potential”, “will” and similar expressions, and are based on Molecular Partners’ current beliefs and expectations. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements. Some of the key factors that could cause actual results to differ from Molecular Partners’ expectations include, but are not limited to, those set forth in under the heading “Risk Factors” in Molecular Partners’ Annual Report on Form 20-F for the year ended December 31, 2024 and other filings Molecular Partners makes with the SEC from time to time. These documents are available on the Investors page of Molecular Partners’ website at www.molecularpartners.com.
Any forward-looking statements speak only as of the date of this press release and are based on information available to Molecular Partners as of the date of this release, and Molecular Partners assumes no obligation to, and does not intend to, update any forward-looking statements, whether as a result of new information, future events or otherwise.?
FAQ**
How does Molecular Partners AG MLLCF plan to leverage its DARPin therapeutics in addressing unmet medical needs in oncology compared to traditional treatment modalities?
Can you elaborate on the strategic partnerships that Molecular Partners AG MLLCF has formed with pharmaceutical companies and academic centers to enhance its pipeline?
What are the key milestones that Molecular Partners AG MLLCF aims to achieve in 2026, particularly concerning the clinical development of its product candidates?
How does the geographic presence of Molecular Partners AG MLLCF in both Zurich-Schlieren and Concord, MA, influence its research and business strategies in the biotech sector?
**MWN-AI FAQ is based on asking OpenAI questions about Molecular Partners AG (NASDAQ: MOLN).
NASDAQ: MOLN
MOLN Trading
-3.72% G/L:
$4.9346 Last:
2,415 Volume:
$4.9407 Open:
